ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2016
Molecular genetic heterogeneity in undifferentiated endometrial carcinomas.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma.Pathology oncology research : POR · 2020Pooled it
- TCGA Molecular Subgroups in Endometrial Undifferentiated/Dedifferentiated Carcinoma.Pathology oncology research : POR · 2020Pooled it
- Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups.Archives of gynecology and obstetrics · 2020Pooled it
- Undifferentiated endometrial carcinoma: a case report.Journal of medical case reports · 2026Article
- Distinct genomic subgroups and mutational patterns in undifferentiated/dedifferentiated endometrial carcinoma.BMC cancer · 2025Article
- Prognostic values of molecular subtypes and SWI/SNF protein expression in de-differentiated/undifferentiated endometrial carcinoma.Histopathology · 2025Article
- Exploring the Genetic and Clinical Landscape of Dedifferentiated Endometrioid Carcinoma.International journal of molecular sciences · 2025Article
- Immune alterations and overexpression of CTCF in endometrial carcinoma: insights from molecular subtyping.Cancer cell international · 2024Article
- Moving into the modern era of molecular classification for endometrial cancer.Journal of surgical oncology · 2024Review
- Dedifferentiated Endometrial Carcinoma: A Rare Aggressive Neoplasm-Clinical, Morphological and Immunohistochemical Features.Cancers · 2023Review
- Generation and Integrated Analysis of Advanced Patient-Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.International journal of molecular sciences · 2022Review
- Rare Subtype of Endometrial Cancer: Undifferentiated/Dedifferentiated Endometrial Carcinoma, from Genetic Aspects to Clinical Practice.International journal of molecular sciences · 2022Review
- The Novel Phosphatase Domain Mutations Q171R and Y65S Switch PTEN from Tumor Suppressor to Oncogene.Cells · 2021Article
- The MCM3AP-AS1/miR-126/VEGF axis regulates cancer cell invasion and migration in endometrioid carcinoma.World journal of surgical oncology · 2021Article
- Cervical malignant mixed mesonephric tumour: A case report with local recurrence after six-years and next-generation sequencing analysis with particular reference to the ataxia telangiectasia mutated gene.Experimental and therapeutic medicine · 2021Article
- Article
- Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel.Pathology oncology research : POR · 2021Article
- The frequency of POLE-mutation in endometrial carcinoma and prognostic implications: a systemic review and meta-analysis.Journal of pathology and translational medicine · 2020Article
- Dedifferentiated Endometrioid Carcinomas with Neuroendocrine Differentiation: A Clinicopathological and Immunohistochemical Study of Three Cases.Cancer management and research · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 7 institutions in 2 countries.
Funding
Abstract
Undifferentiated and dedifferentiated endometrial carcinomas are rare and highly aggressive subtypes of uterine cancer, not well characterized at a molecular level. To investigate whether dedifferentiated carcinomas carry molecular genetic alterations similar to those of pure undifferentiated carcinomas, and to gain insight into the pathogenesis of these tumors, we selected a cohort of 18 undifferentiated endometrial carcinomas, 8 of them with a well-differentiated endometrioid carcinoma component (dedifferentiated endometrioid carcinomas), and studied them by immunohistochemistry and massive parallel and Sanger sequencing. Whole-exome sequencing of the endometrioid and undifferentiated components, as well as normal myometrium, was also carried out in one case. According to The Cancer Genome Atlas classification, we distributed 95% of the undifferentiated carcinomas in this series as follows: (a) hypermutated tumors with loss of any mismatch repair protein expression and microsatellite instability (eight cases, 45%); (b) ultramutated carcinomas carrying mutations in the exonuclease domain of POLE (two cases, 11%); (c) high copy number alterations (copy-number high) tumors group exhibiting only TP53 mutations and high number of alterations detected by FISH (two cases, 11%); and (d) low copy number alterations (copy-number low) tumors with molecular alterations typical of endometrioid endometrial carcinomas (five cases, 28%). Two of the latter cases, however, also had TP53 mutations and higher number of alterations detected by FISH and could have progressed to a copy-number high phenotype. Most dedifferentiated carcinomas belonged to the hypermutated group, whereas pure undifferentiated carcinomas shared molecular genetic alterations with copy-number low or copy-number high tumors. These results indicate that undifferentiated and dedifferentiated endometrial carcinomas are molecularly heterogeneous tumors, which may have prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.